Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.
Article Details
- CitationCopy to clipboard
Bobo WV
Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.
Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70.
- PubMed ID
- 23272794 [ View in PubMed]
- Abstract
This article reviews the pharmacological profile and published efficacy and tolerability/safety data of iloperidone, asenapine and lurasidone, the most recent atypical antipsychotics to be approved in the USA for the treatment of schizophrenia. All three agents are similar in terms of overall efficacy and low propensity for clinically significant weight gain or adverse changes in glycemic or lipid profile. However, these agents differ from one another in terms of formulations, pharmacokinetics, and dosing and nonmetabolic adverse effect profile. For each drug, comparative and real-world effectiveness studies are lacking, as are effectiveness and safety data in elderly, young and pregnant/nursing patients. As such, the exact place of iloperidone, asenapine and lurasidone within the broader antipsychotic armamentarium is currently difficult to establish.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Iloperidone 5-hydroxytryptamine receptor 1A Protein Humans UnknownAntagonistDetails Iloperidone 5-hydroxytryptamine receptor 6 Protein Humans UnknownAntagonistDetails Iloperidone 5-hydroxytryptamine receptor 7 Protein Humans UnknownAntagonistDetails Iloperidone Dopamine D1 receptor Protein Humans UnknownAntagonistDetails Iloperidone Dopamine D4 receptor Protein Humans UnknownAntagonistDetails Iloperidone Histamine H1 receptor Protein Humans UnknownAntagonistDetails